Type 2 inflammation in cystic fibrosis is a predictor of mortality and targeted with CFTR modulator therapy

Letter/Communication

Open access

Daniel P. Cook, Ashley Y. Wu, Christopher M. Thomas, Robert G. Hamilton, Ray Stokes Peebles Jr and Vern Eric Kerchberger

Allergy (Copenhagen)

06/16/2024

DOI: 10.1111/all.16198

PMCID: PMC11657065

PMID: 38881035

Files and links (1)

url

https://doi.org/10.1111/all.16198View

Published (Version of record) Open Access

To the editor

Immunology

Allergy

Life Sciences & Biomedicine

Science & Technology

Title: Subtitle: Type 2 inflammation in cystic fibrosis is a predictor of mortality and targeted with CFTR modulator therapy
Creators: Daniel P. Cook - Vanderbilt University Medical Center
Ashley Y. Wu - Massachusetts General Hospital
Christopher M. Thomas - Vanderbilt University Medical Center
Robert G. Hamilton - Johns Hopkins University
Ray Stokes Peebles Jr - Vanderbilt University
Vern Eric Kerchberger - Vanderbilt University Medical Center
Resource Type: Letter/Communication
Publication Details: Allergy (Copenhagen)
DOI: 10.1111/all.16198
PMID: 38881035
PMCID: PMC11657065
NLM abbreviation: Allergy
ISSN: 0105-4538
eISSN: 1398-9995
Publisher: Wiley
Number of pages: 6
Grant note: U.S. Department of Veterans Affairs; US Department of Veterans Affairs Vanderbilt University Medical Center Adult CF Clinic
Language: English
Date published: 06/16/2024
Academic Unit: Internal Medicine
Record Identifier: 9984695802502771

7 Record Views